CD8A and neoplasm: Immunophenotyping serine-deprived CT26 tumors revealed that tumor-infiltrating CD8+ T cells exhibit multiple markers of terminal dysfunction, notably programmed cell death 1 (PDCD1, best known as PD-1), pointing to the possibility of harnessing a PD-1 blocker to further increase disease control.